Mateos MV., et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet (2019)

Fujisaki T., et al. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Annals of Hematology (2019)

Mateos MV., et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clinical Lymphoma, Myeloma & Leukemia (2019)

Moreau P., et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet (2019)

Facon T., et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. New England Journal of Medicine (2019)

Chari A., et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood (2019)

O'Dwyer M., et al. CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Advances (2019)

Raje N., et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine (2019)

Mikhael J., et al. A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood (2019)

Perrot A., et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood (2018)

Dimopoulos MA., et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica (2018)

Spencer A., et al. Daratumumab plus bortezomib and dexamethasone versus bortezomiband dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica (2018)

Mateos MV., et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. New England Journal of Medicine (2018)

Takamatsu H., et al. A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. British Journal of Haematology (2018)

Takamatsu H. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. Journal Clinical Medicine (2017)

Chari A., et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood (2017)

Takamatsu H., et al. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-celltransplantation. Annals of Oncology (2017)

Dimopoulos MA., et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine (2016)

Korde N., et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncology (2015)

Martinez-Lopez J., et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood (2014)

Vij R., et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clinical Lymphoma Myeloma and Leukemia (2014)

Ladetto M., et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia (2014)

Hay KA., et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells. Blood (2019)

Wood B., et al. Measurable residual disease detection by high throughput sequencing improves risk stratification for pediatric B-ALL. Blood (2018)

Sala Torra O., et al. Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. Biology of Blood and Marrow Transplantation (2017)

Ladetto M., et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia (2014)

Faham M., et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012)

Gawad C., et al. Massive evolution of the immunoglobulin heavy chain locus in children with b precursor acute lymphoblastic leukemia. Blood (2012)

Thompson PA., et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood (2019)

Brown JR., et al. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood (2019)

Aw A., et al. Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leukemia & Lymphoma (2018)

Turtle CJ., et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib. Journal of Clinical Oncology (2017)

Ryan CE., et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood (2016)

Rawstron AC., et al. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia (2016)

Kriangkum J., et al. Single-cell analysis and next-generation immuno-sequencing show that multiple clones persist in patients with chronic lymphocytic leukemia. PLoS ONE (2015)

Wang M., et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia (2019)

Ruan J., et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood (2018)

Chen RW., et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British Journal of Haematology (2017)

Armand P., et al. A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. British Journal of Haematology (2016)

Ladetto M., et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia (2014)